The Conversation (0)
Heat Biologics will present a new poster from a Phase II trial on HS-410 treating non-muscle invasive bladder cancer at the 2017 American Association of Clinical Oncologists annual meeting.
Heat Biologics (NASDAQ:HTBX) will present a new poster from a Phase II trial on HS-410 treating non-muscle invasive bladder cancer at the 2017 American Association of Clinical Oncologists annual meeting.
As quoted in the press release:
Poster Presentation Details:
- Title: Immune response results from vesigenurtacel-l (HS-410) in combination with BCG from a randomized phase 2 trial in patients with non-muscle invasive bladder cancer (NMIBC).
- Date and Time: Sunday, June 4, 8:00 AM to 11:30 AM
- Poster Number: 209
Click here to read the full press release.
Source: www.accesswire.com
